We like to share information about our workplace at AVROBIO.

Our mission: Curing rare diseases in a single dose. We believe: Gene therapy will revolutionize the future.

Here are some of the ways we are living our mission.

In recognition of Gaucher Awareness Month, AVROBIO’s October 2018 contest on Ripples4Rare.com invites patients to share their stories, promotes awareness and raises funds for the National Gaucher Foundation. Enter here

AVROBIO employees appreciated hearing important perspectives about Fabry disease when Jack Johnson, Executive Director and Founder of the Fabry Support & Information Group, visited AVROBIO in September 2018.

On July 9, 2018, the AVROBIO team proudly rang the Nasdaq closing bell to commemorate our IPO milestone as we deliver on our vision to bring new gene therapies to patients with rare diseases.

AVROBIO was nominated for a NEVY 2018 Award by the New England Venture Capital Association in the category Revolutionary New Therapeutic/Platform Startup of the Year.

In 2018, AVROBIO initiated the Ripples4Rare campaign, with a site for people to leave a message that shares a ripple of hope with their thoughts and experiences about rare diseases. Every time a visitor shared the Ripples4Rare page, they added to the participation to help achieve the fund-raising goal. Dedicated to all rare disease organizations, AVROBIO’s focus in 2018 is Fabry International Network (FIN), with a donation goal of $10,000 that was achieved in March 2018.

Rare Disease Day: February 28, 2018

On Rare Disease Day, AVROBIO employees showed their solidarity with patients with rare diseases by getting tattoos on their arms that said “Be Rare. Be You.” The tattoos were temporary, but showed a long-lasting commitment by the AVROBIO team to work every day to bring innovative gene therapies to patients with rare diseases.


We saw it coming at pharma:
Now gene therapy is biotech 2.0 for rare diseases

Published on February 1, 2018
Our Chief Business Officer, Deanna Petersen, shares her industry experience and blogs about “biotech 2.0” and gene therapy’s emergence as one of the most exciting new classes of medicines.  https://lnkd.in/evghY-a